MX2015015487A - NOVEDOSOS HIDRATOS CRISTALINOS DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3 -[5-(4-FLUORO-FENIL)-2-TIENIL-METIL]-BENCENO. - Google Patents

NOVEDOSOS HIDRATOS CRISTALINOS DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3 -[5-(4-FLUORO-FENIL)-2-TIENIL-METIL]-BENCENO.

Info

Publication number
MX2015015487A
MX2015015487A MX2015015487A MX2015015487A MX2015015487A MX 2015015487 A MX2015015487 A MX 2015015487A MX 2015015487 A MX2015015487 A MX 2015015487A MX 2015015487 A MX2015015487 A MX 2015015487A MX 2015015487 A MX2015015487 A MX 2015015487A
Authority
MX
Mexico
Prior art keywords
glucopyranosyl
fluorophenyl
benzene
methyl
crystalline hydrates
Prior art date
Application number
MX2015015487A
Other languages
English (en)
Other versions
MX355831B (es
Inventor
Lovro Selic
Andreas Hotter
Christoph Langes
Ulrich Griesser
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of MX2015015487A publication Critical patent/MX2015015487A/es
Publication of MX355831B publication Critical patent/MX355831B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a hidratos cristalinos no estequiométricos deI 1-(ß-D-glucopiranosil)-4-metil-3-[5-(4-fluoro -fenil)-2-tienil-metil]-benceno, a procesos para su preparación, y a su uso como medicamentos. En adición, la presente invención se refiere a composiciones farmacéuticas que comprenden una cantidad efectiva de los hidratos cristalinos novedosos.
MX2015015487A 2013-05-08 2014-05-07 NOVEDOSOS HIDRATOS CRISTALINOS DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3 -[5-(4-FLUORO-FENIL)-2-TIENIL-METIL]-BENCENO. MX355831B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13166940 2013-05-08
EP14155190 2014-02-14
PCT/EP2014/059281 WO2014180872A1 (en) 2013-05-08 2014-05-07 NOVEL CRYSTALLINE HYDRATES OF 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE

Publications (2)

Publication Number Publication Date
MX2015015487A true MX2015015487A (es) 2016-06-14
MX355831B MX355831B (es) 2018-05-02

Family

ID=50732139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015487A MX355831B (es) 2013-05-08 2014-05-07 NOVEDOSOS HIDRATOS CRISTALINOS DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3 -[5-(4-FLUORO-FENIL)-2-TIENIL-METIL]-BENCENO.

Country Status (7)

Country Link
US (1) US10323056B2 (es)
EP (1) EP2994468B1 (es)
CN (1) CN105358553A (es)
BR (1) BR112015028096B1 (es)
CA (1) CA2911261A1 (es)
MX (1) MX355831B (es)
WO (1) WO2014180872A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3068779A4 (en) * 2013-11-11 2017-06-28 Crystal Pharmatech Co. Ltd. Crystalline forms b, c, and d of canagliflozin
WO2016016774A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Crystalline forms of canagliflozin
EP2990029A1 (en) * 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
CN108003149A (zh) * 2014-12-25 2018-05-08 重庆医药工业研究院有限责任公司 一种卡格列净晶型i及其制备方法
CN104530024B (zh) * 2015-02-04 2017-08-08 上海迪赛诺药业有限公司 1‑(β‑D‑吡喃葡糖基)‑4‑甲基‑3‑[5‑(4‑氟苯基)‑2‑噻吩基甲基]苯的晶型及其制备方法
CN105001214A (zh) * 2015-04-20 2015-10-28 华润赛科药业有限责任公司 一种卡格列净晶型f及其制备方法
EP3298007B1 (en) * 2015-05-22 2020-07-22 Janssen Pharmaceutica NV Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol
CZ2015824A3 (cs) * 2015-11-20 2017-05-31 Zentiva, K.S. Krystalická forma Canagliflozinu a způsob její přípravy
CN108368096B (zh) 2015-12-21 2021-12-10 詹森药业有限公司 用于获得坎格列净半水合物晶体的结晶程序
CN108017626A (zh) * 2016-11-04 2018-05-11 上海奥博生物医药技术有限公司 一种坎格列净半水合物新晶型
CN114213399A (zh) * 2021-12-20 2022-03-22 上海启讯医药科技有限公司 一种卡格列净丙酮水合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP5596545B2 (ja) 2007-09-10 2014-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓｇｌｔの阻害物質として有用な化合物の製造方法
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
SI2451797T1 (sl) 2009-07-10 2013-07-31 Janssen Pharmaceutica, N.V. Postopek kristalizacije 1-(beta-d-glukopiranosil)-4-metil-3-(5-(4-fluorofenil)-2-tienilmetil) benzena
PT2488515T (pt) 2009-10-14 2017-04-11 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt2
EP2498758B1 (en) * 2009-11-13 2018-07-25 AstraZeneca AB Bilayer tablet formulations
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
EP2773359A4 (en) 2011-10-31 2015-10-21 Scinopharm Taiwan Ltd CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS

Also Published As

Publication number Publication date
BR112015028096A2 (pt) 2017-07-25
EP2994468A1 (en) 2016-03-16
CN105358553A (zh) 2016-02-24
MX355831B (es) 2018-05-02
EP2994468B1 (en) 2017-07-19
BR112015028096B1 (pt) 2022-04-26
WO2014180872A1 (en) 2014-11-13
US10323056B2 (en) 2019-06-18
US20160145286A1 (en) 2016-05-26
CA2911261A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
MX2015015487A (es) NOVEDOSOS HIDRATOS CRISTALINOS DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3 -[5-(4-FLUORO-FENIL)-2-TIENIL-METIL]-BENCENO.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12016500094A1 (en) Autotaxin inhibitors
TN2015000278A1 (en) Autotaxin inhibitors
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MX2017007371A (es) Compuestos antibacterianos que tienen un amplio espectro de actividad.
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
MX2017007377A (es) Compuestos organicos.
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PH12015502747A1 (en) Novel compounds for the treatment of cancer
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EP3031465A4 (en) Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
IL243223B (en) History of imidazole, their preparation and pharmaceutical preparations containing them
EP3078671A4 (en) Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative
MX2017007380A (es) Compuestos organicos.

Legal Events

Date Code Title Description
FG Grant or registration